Compound U-76,253A (R-3746), the active metabolite sodium salt of the prodrug ester , was demonstrated to be active against members of the family Enterobacteriaceae with 82 and 85% of strains inhibited by s2.0 and s4.0 ,ug/mI, respectively. In addition, U-76,253A inhibited all strains of Branhamella catarrhalis, Haemophilus influenzae, pathogenic Neisseria spp., oxacillin-susceptible Staphylococcus aureus, beta-hemolytic streptococci, and pneumococci at .4.0 ,ug/ml. Pseudomonas spp., Acinetobacter spp., enterococci, and oxacillin-resistant staphylococci were resistant to U-76,253A. This U-76,253A antimicrobial activity and spectrum was generally superior to that of comparison orally administered cephems (cefaclor, cefuroxime, and cefixime) and the amoxicillin-clavulanic acid combination. Tests with I8-lactamase-producing isolates indicated that U-76,253A was bactericidal and that its MICs were only influenced by high inoculum concentrations (107 CFU/ml) against type Ia and IVc enzyme-producing strains. Preliminary disk diffusion interpretive zone criteria were calculated for 10-and 30-,Ig U-76,253A disks and several possible susceptible MIC breakpoints. The absolute interpretive agreement between MICs and zone diameters ranged from 87.8 to 95.6%. Final selection of interpretive criteria awaits further U-76,252 pharmacokinetic information. 
(R-3746), the sodium salt of U-76,253 used for susceptibility testing, has an antimicrobial activity described as inhibiting gram-positive cocci (MIC for 50% of the strains tested [M'C50], '0.01 to 3.1 ,ug/ml) other than enterococci or oxacillin-resistant staphylococci and most gram-negative bacilli (M'C50, .0.01 to 12.5 jig/ml) except the Pseudomonas species (3, 17) . Early investigations also showed that U-76,252 was free of toxicity, 41% bound to serum proteins, P-lactamase stable, and well absorbed from the gastrointestinal tract (3, 17 ; T. Komai, K. Fujimoto, M. Sekine, and H. Masuda, 26th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 593, 1986) . In this report, we summarize the results of defining the U-76,253A spectrum of antimicrobial activity, effects of inoculum on U-76,253A MICs, bactericidal activity, U-76,253A activity on 3-lactamase-producing isolates, and the development of in vitro disk diffusion tests with 10-or 30-jug U-76,253A disks.
MATERIALS AND METHODS
Antimicrobial agents. The U-76,253A was provided by The Upjohn Co. This formulation is the sodium salt of the free acid metabolite R-3763 or U-76,253. The other comparison P-lactams (cefaclor, cefuroxime, cefixime, amoxicillin, and clavulanic acid) were supplied by their respective manufacturers in the United States.
* Corresponding author.
The U-76,253A disks were produced with a drug content of 10 or 30 jig by The Clinical Microbiology Institute. The comparison 30-jig cefotaxime disks were manufactured by BBL Microbiology Systems (Cockeysville, Md.).
Bacterial strains. Recent isolates typical of current clinical strains were collected from five geographically diverse microbiology laboratories and from the stock culture collections at The Clinical Microbiology Institute and The Centers for Disease Control (Atlanta, Ga.). The strains were stored at -60°C or below until processed. The 694 organisms were tested (see Tables 1 and 2 ) and had the following general distribution: 218 members of the family Enterobacteriaceae (14 species), 10 Acinetobacter spp., 20 Branhamella catarrhalis, 72 Haemophilus influenzae (includes 24 strains resistant to ampicillin or chloramphenicol), 58 beta-hemolytic streptococci, and 20 Streptococcus pneumoniae (10 resistant to penicillin). Several other strains were also tested that produced various well-characterized ,Blactamases.
Susceptibility testing methods. Broth microdilution test trays were prepared by Prepared Media Laboratory (Tualatin, Oreg.), and tests were performed by the method of the National Committee for Clinical Laboratory Standards (NCCLS) (10) . The test broth was supplemented with 3% lysed horse blood for testing beta-hemolytic Streptococcus spp., Streptococcus pneumoniae, and H. influenzae (10) . Anaerobic organisms were tested in Wilkins-Chalgren agar by the agar dilution method described by the NCCLS (11) . These studies were performed in two laboratories with sufficient controls to document the comparability of the testing procedures. Disk agar diffusion tests were also performed and followed the current M2-A3 procedure (9) . Citrobacter diversus (10) Citrobacterfreundii (10) Enterobacter aerogenes (19) Enterobacter agglomerans (10) Enterobacter cloacae (20) (2) . Susceptibility for U-76,253A was a breakpoint concentration of s2.0 ,ug/ml, with data for c4.0 F.g/ml in parentheses.
d Only four isolates were 1-lactamase negative.
I All strains were also ,-lactamase negative and ampicillin susceptible by disk and dilution tests. f Includes Klebsiella oxytoca (4 strains) and Klebsiella pneumoniae (21 strains).
Interpretive zone standards were selected by correlating zone diameters with MICs by using both regression analysis (method of least squares) and the error-rate bounding method of Metzler and DeHaan (8) .
The MBC was defined as the lowest concentration producing a .99.9% reduction in the CFU from the initial 5 x 105-CFU/ml inoculum concentration at 24 h. The CFU per milliliter determinations were done by the methods of the NCCLS (12) and the rejection criteria of Pearson et al. (15) , by replicate subculturing of 10-pd inoculum volumes to drug-free agar plates. The effects on U-76,253A MICs of altering the inoculum concentrations were determined by using inoculum sizes of approximately 1 x 104, 5 x 105, and 1 x 107 CFU/ml (see Table 3 ).
RESULTS
Antimicrobial activity against members of the Enterobacteriaceae. MICs of six orally administered 1-lactams for 14 members of the Enterobacteriaceae are found in Table 1. The U-76,253A MIC50s ranged from -0.06 to 8.0 ,g/ml.
Greater than 90% of strains tested within each species were considered U-76,253A susceptible (c4.0 ,ug/ml) except The beta-hemolytic streptococci (Streptococcus agalactiae and Streptococcus pyogenes) were all susceptible to the tested oral cephalosporins and penicillins. The penicillinsusceptible pneumococci were also very susceptible to all P-lactams. In contrast, the MICs for the penicillin-resistant Streptococcus pneumoniae strains were approximately 16-fold higher, compromising the spectrum of some tested cephalosporins such as cefixime and cefaclor (MIC%0s, 8 .0 ,ug/ml).
Bactericidal activity and inoculum effects. Table 3 lists the results of a limited number of bactericidal activity determinations (12, 15) and the MICs for 14 selected organisms with known P-lactamase-mediated resistances. U-76,253A was generally bactericidal at a concentration equal to or up to fourfold higher than the measured MIC. The effects of increasing the inoculum concentration on the U-76,253A MICs revealed minimal adverse elevations by the increase from 1 x 104 to 5 x 105 CFU/ml. However, some marked inoculum effects were identified for some strains producing chromosome-mediated ,-lactamases when the inoculum was raised from 5 x 105 to 1 x 107 CFU/ml.
The MICs of U-76,253A for six additional strains of Escherichia coli producing plasmid-mediated f-lactamases (TEM-2, OXA-1, OXA-3, OXA-4, SHV-1, and HMS-1) ranged from 0.25 to 1.0 jig/ml at an inoculum concentration of 5 x 105 CFU/ml.
Disk diffusion test results. Table 4 and Fig. 1 show the results of regression line comparisons of U-76,253A MICs and investigator-prepared disks (10 and 30 ,ug) . The 30-,ug disk produced zones which were 4 mm larger than those observed with the 10-,ug disk. The correlation (r) between these two disk concentration zones was 0.93 with the equation y = -5.9 + 1.1x, using 564 zone-diameter pairs.
The scattergrams for the 10-,ug disk show the calculated 
DISCUSSION
Significant advances have been made in the last decade to expand the spectrum and potency of the parenteral ,Blactams. During that interval, little progress was forthcoming in the development of oral cephems having the same improved potencies and maintaining the high degree of intestinal absorption found in earlier D-phenylglycine-substituted drugs. Recently, several C-4-esterified cephalosporins (3-5, 13, 14, 17, 18) have been developed by using the 7-methoxyimino structure. These cephem esters are efficiently converted by gut wall carboxyl esterases to active free forms that most resemble the parenteral 7-methoxyimino aminothiazolyl drugs such as cefotaxime, ceftizoxime, and cefmenoxime.
U-76,252 (CS-807; Sankyo) is a 1-isopropoxycarbonyloxy ethyl ester of U-76,253A, a sodium salt of a very active 7-methoxyimino aminothiazolyl cephalosporin (3, 17) . We confirmed its very wide spectrum of potent antimicrobial action against the enteric bacilli (82 to 85% susceptible), Branhamella catarrhalis, H. influenzae, the pathogenic Neisseria species, oxacillin-susceptible staphylococci, and the Streptococcus spp. (3, 17) . These results place U-76,253A as comparable to cefetamet (Ro 15-8074) (5, 18) and cefteram (Ro 19-5247 or T-2525) (5, 14, 17, 18) against members of the Enterobacteriaceae but superior to these other cephems against the gram-positive cocci. Cefuroxime was equal to U-76,253A when tested against the staphylococci and Streptococcus species but lacks the U-76,253A gram-negative spectrum (4, 13). U-76,253A was also more active or had a wider potential spectrum than the nonesterified investigational cephalosporins, cefixime (FK-027) (2, 6, 17) and BMY-28100 (7).
The U-76,253A spectrum was favorably influenced by its apparent ,3-lactamase stability (17) . Its enzyme stability was similar to that of cefteram (14, 17) or cefixime (17) and superior to that of other orally administered cephalosporins such as cephalexin, cefaclor, and BMY-28100 (7, 14, 17) .
Pneumococci resistant to penicillin (19) were less susceptible to the tested cephalosporins in this and other studies (1, 19) . U-76,253A was the most active oral agent tested against these strains (MIC100, 1.0 pug/ml) but this activity was 16-fold less than that observed against the penicillin-susceptible isolates. Cefixime and cefaclor exhibited compromised activity against the penicillin-resistant pneumococci (1) .
For U-76,252 (CS-807), like most other cephalosporin esters, there is little published information about human pharmacokinetics. Therefore, we present several disk test interpretive options that may be reevaluated as more statistics on U-76,252 concentration in serum become available (5) . Preliminary human pharmacokinetic studies (data on file, The Upjohn Co.) indicate that 1.0 jig of U-76,253A per ml can be achieved for every 100-mg U-76,252 oral dose or serum peaks of 4 to 6 jig/ml with usual regimens. This serum level was approximately 30 to 35% of that obtained with a similar dose of cefaclor; however, the U-76,253A elimination half-life was longer, 1.8 to 2.7 h. When the U-76,253A susceptible MIC breakpoint becomes more established, the drug may be compared with and positioned among the currently available oral cephalosporins. At all proposed MIC breakpoints ('1.0, s2.0, or c4.0 ,ug/ml), U-76,253A appears to be significantly more active than cephalexin, cephradine, cefadroxil, and cefaclor. These differences require separate testing of U-76,253A rather than relying on the use of cephalothin as a class representative (9, 10, 16) .
Our in vitro studies indicated U-76,252 to be a promising oral cephem ester with a wide potential spectrum of antimicrobial activity. We await the clarification of the U-76,253A
human serum concentrations and the definition of its final clinically useful spectrum.
